Concomitant chemoradiation therapy with UFT and low dose CDDP for T2 glottic carcinomas. Predictive value of MR imaging

To improve the local control of T2-stage glottic carcinomas, we performed concomitant chemoradiation therapy with UFT (uracil and tegafur) and low dose cisplatin (CDDP). The predictive value of MR findings was also evaluated. Thirty six patients with T2N0-stage glottic carcinomas were included in this study. Tumors adjacent to the thyroid cartilage on MRI were classified as adjacent'', and undetectable tumors or tumors separate from the cartilage were classified as ''intact''. Radiation therapy with 64 Gy/32 fractions was delivered by 4 MV linear accelerator. Intravenous infusion of CDDP (4 mg/m2) and oral administration of UFT (450 mg/body) were continued concomitantly from day one of irradiation for four weeks. Kaplan-Meier methods were used to estimate the time to local recurrence distribution. Differences were determined using log-rank tests for univariate analysis. No severe acute and late adverse effects (grade 3 or more) were observed. Two-year local control rate with chemoradiation therapy was 82%. According to MR findings, local control rates were 95% for intact lesions (n=20) and 68% for adjacent lesions (n=16) (p=0.0249). Concomitant chemoradiation therapy with UFT and low dose CDDP was considered to be effective for T2-stage glottic carcinomas. However, the results were not enough for tumors adjacent to the thyroid cartilage on MRI. (author)